Retirement Guys Formula LLC Boosts Position in Johnson & Johnson (NYSE:JNJ)

Retirement Guys Formula LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 28.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,619 shares of the company's stock after purchasing an additional 1,698 shares during the period. Retirement Guys Formula LLC's holdings in Johnson & Johnson were worth $1,263,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. MRP Capital Investments LLC lifted its holdings in shares of Johnson & Johnson by 4.1% in the 4th quarter. MRP Capital Investments LLC now owns 1,640 shares of the company's stock worth $237,000 after purchasing an additional 65 shares in the last quarter. Syverson Strege & Co lifted its holdings in shares of Johnson & Johnson by 4.9% in the 4th quarter. Syverson Strege & Co now owns 1,394 shares of the company's stock worth $202,000 after purchasing an additional 65 shares in the last quarter. Denali Advisors LLC lifted its holdings in shares of Johnson & Johnson by 1.3% in the 4th quarter. Denali Advisors LLC now owns 5,128 shares of the company's stock worth $742,000 after purchasing an additional 67 shares in the last quarter. Sage Mountain Advisors LLC lifted its holdings in shares of Johnson & Johnson by 0.5% in the 4th quarter. Sage Mountain Advisors LLC now owns 14,564 shares of the company's stock worth $2,106,000 after purchasing an additional 67 shares in the last quarter. Finally, Sovereign Financial Group Inc. lifted its holdings in shares of Johnson & Johnson by 1.8% in the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock worth $651,000 after purchasing an additional 69 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

JNJ has been the topic of several recent analyst reports. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Morgan Stanley raised their price objective on Johnson & Johnson from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Wednesday, April 16th. Raymond James Financial dropped their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Royal Bank Of Canada restated an "outperform" rating and set a $181.00 price objective on shares of Johnson & Johnson in a research note on Thursday, June 5th. Finally, Bank of America dropped their price objective on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a research note on Thursday, April 10th. Eleven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Stock Performance

JNJ traded up $0.43 during trading hours on Friday, hitting $152.44. The stock had a trading volume of 9,999,068 shares, compared to its average volume of 8,028,733. The company's fifty day simple moving average is $153.85 and its 200 day simple moving average is $153.69. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The stock has a market cap of $366.78 billion, a PE ratio of 16.96, a price-to-earnings-growth ratio of 2.30 and a beta of 0.42. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The company had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were issued a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.41%. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio (DPR) is 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.